Atrial Fibrillation (AF) complicating an acute myocardial infarction (AMI) is frequent and associated with a worse prognosis after MI, particularly because of lethal heart failure (HF) episodes and cardiogenic shock. Although silent AF has also been suggested to be common in AMI, its association with development of heart failure during the first days after AMI remains unknown. In this study we aimed to assess a potential association between silent AF and episodes of heart failure after AMI.
Atrial Fibrillation (AF) complicating an acute myocardial infarction (AMI) is frequent and associated with a worse prognosis after MI, particularly because of lethal heart failure (HF) episodes and cardiogenic shock. Although silent AF has also been suggested to be common in AMI, its association with development of heart failure during the first days after AMI remains unknown. In this study we aimed to assess a potential association between silent AF and episodes of heart failure after AMI.
Methods: For AF screening, 581 consecutive AMI were prospectively analyzed by Continuous ECG Scope Monitoring (CSM) for 48H after hospital admission. Left Ventricular Ejection Fraction (LVEF) was determined on admission by echocardiography. We analyzed the study population into 3 groups: No AF, silent AF (asymptomatic episodes of AF lasting at least >30 sec) and symptomatic AF (symptomatic episodes of AF that lasted ≥12 hours). Diagnosis of heart failure episode was based on plasmatic level of Nt-ProBNP.
Results: Ninety-five (16.4%) patients had AF on CSM after MI, of whom 76 (80%) developed silent AF. Compared with No AF group, patients with silent AF were markedly older (80 (69-85) vs 62 (53-74);p<0.001), more frequently women (45 vs 27%;p=0.006), hypertensive (76vs52%;p<0.001) but less smoker (18vs38%;p<0.001). On admission, patients with silent AF had animpaired LVEF (46%(13) vs 54%(11);p<0.001), with higher Nt-ProBNP (1817 (556-7078) vs435 (111-1512);p<0.001) and more frequent episode of heart failure (42 vs21%;p<0.001).Comparing the three groups, heart failure episodes during the acute phase after myocardial infarction were more frequent in silent AF group (42%) and in symptomatic AF group (53%)than in noAF group (21%), with p<0.001.
Conclusion:
This studyshows that silent AF is very common after MI (16.4%), and highlights for the first time that itis significantly associated with episodes of heart failure. This outcome suggests the potential impact of silent AF on the prognosis of patients after AMI.
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Long-term follow-up after implantable cardioverter defibrillator in patients with Brugada syndrome: a multicenter French experience Aimé Bonny (1), Amara Walid (2), Hasnaa Salih (2), Joelci Tonet (3), Stéphane Dennetierre (1), Guy Fontaine (3), Robert Frank (3), Françoise Hidden-Lucet (3) (1) CH Roubaix, Roubaix, France -(2) CH Montfermeil, Montfermeil, France -(3) Hôpital Pitié-Salpêtrière, cardiologie, unité rythmologie, Paris, France Background and objective: Implantation of a cardioverter defibrillator (ICD) is a frequently recommended treatment for symptomatic Brugada syndrome (BrS). However, complications related to the device have been reported.
Methods and results:
We assessed the benefit / morbidity ratio of this mode of therapy in a cohort of 34 patients implanted in 3 French experienced centers between January 1, 2002 and November 30, 2010 . The mean age was 48±14 years, 4 (12%) female. Twenty nine (85%) patients had spontaneous typical coved Type I ECG pattern, 15 (44%) had family history of sudden cardiac death (SCD) and 24 (88%) had positive EP study. ICD implantation was based on aborted sudden cardiac arrest (SCA) in 3 (9%), syncope in 19 (56%) or high risk status (spontaneous type 1 ECG in conjunction with a family history of SCD and/or a positive EP study) in 12 (35%). The median follow-up period was 74±23 (9-127) months. One patient with prior cardiac arrest died of a non-cardiac cause, 5 (15%) patients had appropriate device therapy; all with spontaneous type I ECG and previous syncope but none with prior cardiac arrest. Overall complication rate was 26%. Six (27%) symptomatic and 3 (25%) asymptomatic patients experienced complications. Five (14%) patients (4 with previous syncope and 1 asymptomatic) experienced inappropriate shocks and 4 (12%) had other complications: 2 patients had lead rupture, 1 lead displacement, and 1 pneumothorax during device replacement. These complications occurred in 2 asymptomatic and 2 symptomatic (1 syncope and 1 prior aborted SCA) patients. No case of SCD was observed in ICD carriers.
Conclusion:
Appropriate device therapy after a median follow-up period of 6 years was observed in patients with prior syncope and none in asymptomatic patients. Complication rate was leading not to recommend ICD implantation in asymptomatic Brugada patients and to carefully evaluate the risk / morbidity ratio in subject with non spontaneous coved type ECG pattern.
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